New perspectives in the diagnosis and evolution of the consumption of tobacco: Markers of susceptibility and damage;Nuevas perspectivas en el diagnóstico y la evolución del consumo de tabaco: Marcadores de susceptibilidad y lesión

Medicina Clinica

Volumn 126, Issue 16, 2006, Pages 628-631

  Pérez Trullén, Alfonso ^a   Bartolomé, Cruz Belén ^b   Banegas, José Ramón ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b MEDICINA FAMILIAR Y COMUNITARIA   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Functional markers; Genetic markers; Quality of life; Tobacco

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CYTOPATHOLOGY; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; LUNG CARCINOMA; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; TOBACCO;

EID: 33745053135     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13087722     Document Type: Review

References (24)

1. Global Youth Tobacco Survey Collaborating Group (GYTS). Differences in worldwide tobacco use by gender: findings from the global youth tobacco survey. J Sch Health. 2003;73:207-15.
2. Pérez Trullén A, Herrero I, Clemente ML, Marrón R. Marcadores biológicos y funcionales para la determinación de exposición y evolución de los fumadores. En: Jiménez A, Fagerström K, editores. Tratado de tabaquismo. Madrid: Grupo Aula Médica; 2004. p. 299-314.
3. Munafó MR, Clark TG, Johnstone EC, Murphy MF, Walton RT. The genetic basis for smoking behaviours a systematic review and meta-analysis. Nicotine Tob Res. 2004;6:583-97.
4. Li MD, Ma JZ, Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Genet. 2004;66:382-92.
5. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adults twins. Addiction. 2003;98:23-31.
6. Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implicatins for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev. 2001;10:733-4.
7. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day INM, Miller G. Apolipoprotein E4 and coronary heart disease in mild-aged men who smoke: a prospective study. Lancet. 2001;358:115-9.
8. Lomas DA, Silverman EK. The genetics of chronic obstructive pulmonary disease. Respir Res. 2001;2:20-6.
9. Alonso Díaz A. Estudio de la correlación genotipo-fenotipo en individuos con hábito tabáquico [tesis doctoral]. Salamanca: Facultad de Medicina. Universidad de Salamanca; 2004.
10. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, the GOLD Scientific Committee. Global strategy tor the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD). Am J Respir Crit Care Med. 2001;163:1256-76.
11. Celedón JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DI. The transforming growth factor beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet. 2004;13: 1649-56.
12. Vineis P, Veglia F, Benhamou S, Butkiewicz D, Cascorbi I, Clapper ML, et al. CYP1A1 T3801 C polymorphisms and lung cancer: a pooled analysis of 2451 cases and 3358 controls. Int J Cancer. 2003;104:650-7.
13. Habdous M, Siest G, Herbeth B, Vincent-Viry M, Visvikis S. Glutathione S-transferases genetic polymorphisms and human diseases: overview of epidemiological studies. Ann Biol Clin. 2004;62:15-24.
14. Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiera T, Saito T, et al. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis. 2004;25:1395-401.
15. Schoket B, Phillips DH, Kostic S, Vincze I. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 Mspl and GSTM1 genotypes in lung patients. Carcinogenesis. 1998;19:841-6.
16. Somers V, Pietersen A, Theunissen P, Theunissen F. Detection of K-ras point mutation in sputum from patients with adenocarcinoma of the lung by point-exact. J Clin Oncol. 1998;16:3061-8.
17. Clemente ML, Pérez-Trullén A, Rubio E, Marrón R, Herrero I. Correlación entre los niveles de monóxido de carbono en el aire espirado y los sistemas de medición de la dependencia nicotínica DSM-IV, test de Fagerström y ARU-SMQ-9 en adolescentes fumadores. Med Clin (Barc). 2003;121:89-94.
18. Ramos A, Oteen B, García-Salmones M. Estudio clínico y diagnóstico del fumador. En: Jiménez C, Solano S, editor. Tabaquismo. Vol. 7. Madrid. Ergón; 2004. p. 87-99.
19. Pérez-Trullén A, Clemente ML, Hernández MA, Morales C. La autoeficacia como método de deshabituación tabáquica. Anales de Psiquiatría. 2001;7:22-9.
20. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ. 2003;37:653-4.
21. Wilson D, Parsons J, Wakefield M. The health-related quality-of-life of never smokers, ex-smokers, and light, moderate, and heavy smokers. Prev Med. 1999;29:139-44.
22. Tillmann M, Silcock J. A comparison of smokers' and ex-smokers' health-related quality of life. J Public Health Med. 1997;19:268-73.
23. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, Leriche J, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst. 1997;89:1366-73.
24. Roland M, Rudd RM. Somatic mutations in the development of lung cancer. Thorax. 1998;53:979-83.